🔗 Share this article

The first new treatments for gonorrhoea in decades are being hailed as a "major milestone" in the effort against drug-resistant strains of the bacteria, according to scientists.

An International Public Health Issue

Cases of gonorrhoea are increasing worldwide, with figures suggesting more than 82 million infections each year. Particularly high rates are observed in the African continent and nations within the World Health Organization's Western Pacific region, which spans from China and Mongolia to New Zealand. Across England, cases have hit a historical peak, while rates across Europe in 2023 were triple the level compared to the rates from 2014.

“The clearance of fresh medications for gonorrhoea is an critical and opportune development in the context of increasing worldwide cases, the spread of superbugs and the extremely scarce therapeutic options at this time.”

Health officials are particularly alarmed about the increase in antibiotic-resistant strains. The World Health Organization has listed it as a "priority pathogen". Recent surveillance found that resistance to key first-line drugs like cefixime and ceftriaxone jumped significantly between 2022 and 2024.

Two New Treatment Options Secure Clearance

Zoliflodacin, also known as a brand name, was authorized by the US Food and Drug Administration in December for combating gonorrhoea. This STI can lead to significant complications, including infertility. Researchers believe that targeted use of this new drug will help delay the spread of drug resistance.

Another new antibiotic, created by the drugmaker GSK, was also approved in concurrent days. This drug, which is additionally indicated for urinary tract infections, was shown in trials to be able to combat drug-resistant strains of the gonorrhoea bacteria.

A Novel Partnership

This new treatment was the result of a innovative non-profit model for drug creation. The charitable organization GARDP collaborated with the pharmaceutical company Innoviva to bring it to fruition.

“This milestone signifies a huge turning point in the therapy of multidrug-resistant gonorrhoea, which previously has been evolving faster than medical innovation.”

Research Study Data and Worldwide Availability

According to data released by a prominent scientific publication, the new drug successfully treated more than 90% of genital gonorrhoea infections. This places it at an equal footing with the current standard treatment, which involves two antibiotics. The trial included over 900 participants from various regions including Belgium, the Netherlands, South Africa, Thailand and the US.

Through the arrangement of its unique model, GARDP has the authority to register and commercialise the drug in numerous low-income and middle-income countries.

Doctors on the front lines have shared optimism. The availability of a easy-to-administer therapy of this kind is described as a "revolutionary step" for gonorrhoea control. This is considered crucial to alleviate the strain of the disease for patients and to prevent the spread of untreatable gonorrhoea worldwide.